{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:21:31Z","timestamp":1784546491933,"version":"3.55.0"},"reference-count":18,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Sanofi K.K."},{"name":"Creativ-Ceutical"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The real\u2010world evidence on the profiles of patients suffering from atopic dermatitis (<jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>) in Japan is sparse. A retrospective claim database analysis was conducted to estimate the health\u2010care resource use (<jats:styled-content style=\"fixed-case\">HCRU<\/jats:styled-content>) and current <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> treatment. Data from October 2013 to September 2016 were extracted from the <jats:styled-content style=\"fixed-case\">JMDC<\/jats:styled-content> (Tokyo, Japan) claims database. <jats:styled-content style=\"fixed-case\">HCRU<\/jats:styled-content> was assessed by a comparison of <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> patients and matched non\u2010<jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> controls. A multivariate analysis was performed to estimate <jats:styled-content style=\"fixed-case\">HCRU<\/jats:styled-content> attributable to <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>. <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a039\u00a0893) have more claims of certain diagnoses such as rhinitis, viral and fungal infections, sleep disorders and conjunctivitis as well as higher <jats:styled-content style=\"fixed-case\">HCRU<\/jats:styled-content> (outpatient visits, prescriptions of <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>\u2010related and non\u2010<jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>\u2010related medications, phototherapy, laboratory tests) than matched non\u2010<jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> controls (<jats:italic>n<\/jats:italic>\u00a0=\u00a039\u00a0893). Treatment pattern analysis included treatment\u2010naive patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a08478) and previously treated <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a030\u00a0109). Approximately 20% of previously treated patients were on the continuous systemic treatment during 18\u2010month follow up. Systemic corticosteroids were the most frequently used systemic treatments. Oral cyclosporin was less frequently used in both groups, but for the longest duration. Almost half of previously treated patients with oral cyclosporin continued treatment for more than 3\u00a0months. In conclusion, <jats:styled-content style=\"fixed-case\">HCRU<\/jats:styled-content> was higher in <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> patients than non\u2010<jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> controls, indicating a high burden of the disease imposed on <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> patients. Continuous administration of systemic treatment, such as oral cyclosporin, systemic corticosteroids and phototherapy, observed in <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> patients sheds light on the difficulties of managing <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> in Japanese clinical practise.<\/jats:p>","DOI":"10.1111\/1346-8138.14947","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T10:01:10Z","timestamp":1561629670000},"page":"652-661","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Health\u2010care resource use and current treatment of adult atopic dermatitis patients in Japan: A retrospective claims database analysis"],"prefix":"10.1111","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3589-7981","authenticated-orcid":false,"given":"Atsuyuki","family":"Igarashi","sequence":"first","affiliation":[{"name":"Division of Dermatology NTT Medical Center Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[{"name":"Sanofi Genzyme Medical Operations Sanofi K.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0607-8787","authenticated-orcid":false,"given":"Kazuhiko","family":"Arima","sequence":"additional","affiliation":[{"name":"Sanofi Genzyme Medical Operations Sanofi K.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Inoue","sequence":"additional","affiliation":[{"name":"Sanofi Genzyme Medical Operations Sanofi K.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dorey","sequence":"additional","affiliation":[{"name":"HEOR Creativ\u2010Ceutical Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Fukushima","sequence":"additional","affiliation":[{"name":"HEOR Creativ\u2010Ceutical Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurie","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Market Access Sanofi K.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,27]]},"reference":[{"issue":"12","key":"e_1_2_7_2_1","first-page":"2431","article-title":"Clinical practice guidelines for the management of atopic dermatitis","volume":"128","author":"Katoh N","year":"2018","journal-title":"Jpn J Dermatol"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000370220"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.09.035"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13401"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12331"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.09.029"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.12.003"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.030"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0383-4"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2001.00120.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.02.003"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14218"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0582-z"},{"issue":"10","key":"e_1_2_7_17_1","first-page":"26","article-title":"The direct and indirect cost burden of atopic dermatitis: an employer\u2010payer perspective","volume":"20","author":"Fowler JF","year":"2007","journal-title":"Manag Care Interface"},{"key":"e_1_2_7_18_1","unstructured":"KawaharaK.Study on socio\u2010economic benefits and loss of allergic diseases (H23\u2010H25 MHLW study) 2013."},{"key":"e_1_2_7_19_1","unstructured":"PMDA.Neoral package insert. Secondary Neoral package insert 2018.https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/300242_3999004M3021_2_28."}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.14947","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.14947","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.14947","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.14947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T20:52:21Z","timestamp":1693342341000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.14947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,27]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/1346-8138.14947"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.14947","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,27]]},"assertion":[{"value":"2019-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}